Price Action To Observe: What’s Neurocrine Biosciences, Inc. Downside After Today’s Big Decline?

Price Action To Observe: What's Neurocrine Biosciences, Inc. Downside After Today's Big Decline?

The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a huge mover today! The stock decreased 3.36% or $1.84 during the last trading session, hitting $52.93. About 1.23M shares traded hands or 20.59% up from the average. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has risen 18.73% since April 13, 2016 and is uptrending. It has outperformed by 14.80% the S&P500.
The move comes after 7 months negative chart setup for the $4.79 billion company. It was reported on Nov, 15 by We have $49.75 PT which if reached, will make NASDAQ:NBIX worth $287.40M less.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Ratings Coverage

Out of 7 analysts covering Neurocrine Biosci (NASDAQ:NBIX), 7 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Neurocrine Biosci has been the topic of 7 analyst reports since August 18, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Leerink Swann on Monday, October 12. Piper Jaffray maintained the stock with “Overweight” rating in Thursday, October 8 report. The stock of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has “Buy” rating given on Tuesday, October 18 by Needham. The rating was initiated by BMO Capital Markets with “Outperform” on Thursday, April 7. H.C. Wainwright initiated the shares of NBIX in a report on Wednesday, June 29 with “Buy” rating. As per Thursday, November 3, the company rating was initiated by Deutsche Bank. The firm has “Buy” rating by Jefferies given on Tuesday, August 18.

According to Zacks Investment Research, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The company’s neuroscience, endocrine and immunology disciplines provide a unique biological understanding of the molecular interaction between central nervous, immune and endocrine systems for the development of therapeutic interventions for anxiety, depression, insomnia, stroke, malignant brain tumors, multiple sclerosis, obesity and diabetes.”

Insitutional Activity: The institutional sentiment decreased to 0.89 in 2016 Q2. Its down 0.21, from 1.1 in 2016Q1. The ratio fall, as 18 funds sold all Neurocrine Biosciences, Inc. shares owned while 89 reduced positions. 37 funds bought stakes while 58 increased positions. They now own 83.14 million shares or 3.77% less from 86.40 million shares in 2016Q1.
Ameriprise Finance Inc holds 0.01% or 199,054 shares in its portfolio. Diam Ltd has invested 0.12% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Credit Suisse Ag reported 320,406 shares or 0.02% of all its holdings. Weiss Multi holds 0.11% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 31,347 shares. Blackrock Advsrs Ltd Liability has 960,256 shares for 0.04% of their US portfolio. Principal Group Incorporated holds 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) for 153,441 shares. American Group Inc Inc, a New York-based fund reported 2,119 shares. Swiss Bankshares last reported 142,000 shares in the company. Northern Tru accumulated 0.01% or 455,366 shares. Fortaleza Asset last reported 0.12% of its portfolio in the stock. First Republic Mgmt has invested 0.01% of its portfolio in Neurocrine Biosciences, Inc. (NASDAQ:NBIX). Wellington Management Group Incorporated Limited Liability Partnership owns 460,074 shares or 0.01% of their US portfolio. Enterprise owns 215 shares or 0.01% of their US portfolio. Financial Bank Of Montreal Can reported 720 shares or 0% of all its holdings. Dimensional Fund Advisors Limited Partnership owns 143,432 shares or 0% of their US portfolio.

Insider Transactions: Since May 16, 2016, the stock had 0 insider buys, and 6 insider sales for $3.08 million net activity. $450,000 worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was sold by Lloyd-Smith Malcolm. $1.13M worth of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares were sold by OBrien Christopher Flint. $700,800 worth of shares were sold by POPS RICHARD F on Wednesday, May 25. Nevinny Corinne H had sold 5,000 shares worth $242,700.

More important recent Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news were published by: which released: “Neurocrine Biosciences to Present at the Credit Suisse 25th Annual Healthcare …” on October 31, 2016, also published article titled: “Neurocrine Biosciences Announces Conference Call and Webcast to Report Third …”, published: “Neurocrine Biosciences Stock Could See A Run-Up” on November 09, 2016. More interesting news about Neurocrine Biosciences, Inc. (NASDAQ:NBIX) was released by: and their article: “Why Neurocrine Biosciences Inc.’s Stock Skyrocketed 147% Higher in 2015” with publication date: January 14, 2016.

NBIX Company Profile

Neurocrine Biosciences, Inc., incorporated on March 20, 1996, is engaged in the development of pharmaceutical products focused on neurological and endocrine diseases and disorders. The Company’s two lead late-stage clinical programs are Elagolix, a gonadotropin-releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie), and NBI-98854 (valbenazine), a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. The Firm focuses on developing NBI-640756 against Essential tremor. The Company’s research and development focuses on addressing diseases and disorders of the central nervous and endocrine systems, which include therapeutic categories ranging from hypothalamic-pituitary-adrenal (HPA) disorders to stress-related disorders and neurological/neuropsychiatric diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment